UA68365C2 - Peroral contraception by combination of anti-estrogen and progestin - Google Patents
Peroral contraception by combination of anti-estrogen and progestin Download PDFInfo
- Publication number
- UA68365C2 UA68365C2 UA2000063196A UA2000063196A UA68365C2 UA 68365 C2 UA68365 C2 UA 68365C2 UA 2000063196 A UA2000063196 A UA 2000063196A UA 2000063196 A UA2000063196 A UA 2000063196A UA 68365 C2 UA68365 C2 UA 68365C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ethoxy
- benzyl
- methyl
- indol
- piperidin
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 39
- 239000000328 estrogen antagonist Substances 0.000 title claims abstract description 36
- 229940046836 anti-estrogen Drugs 0.000 title claims abstract description 35
- 230000001833 anti-estrogenic effect Effects 0.000 title claims abstract description 35
- 230000000708 anti-progestin effect Effects 0.000 title claims 2
- 239000003418 antiprogestin Substances 0.000 title claims 2
- 239000000583 progesterone congener Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000027758 ovulation cycle Effects 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 37
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 19
- 229960004400 levonorgestrel Drugs 0.000 claims description 19
- -1 Z-ketodesogestrel Chemical compound 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 239000003433 contraceptive agent Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000002254 contraceptive effect Effects 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229940053934 norethindrone Drugs 0.000 claims description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 5
- 229960000978 cyproterone acetate Drugs 0.000 claims description 5
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 5
- 229960004976 desogestrel Drugs 0.000 claims description 5
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 5
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 5
- 229960003309 dienogest Drugs 0.000 claims description 5
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004845 drospirenone Drugs 0.000 claims description 5
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229960001652 norethindrone acetate Drugs 0.000 claims description 5
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 5
- 229960000417 norgestimate Drugs 0.000 claims description 5
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 5
- 229950008546 trimegestone Drugs 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims description 2
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229950004203 droloxifene Drugs 0.000 claims description 2
- 229950002248 idoxifene Drugs 0.000 claims description 2
- QZUHFMXJZOUZFI-ZQHSETAFSA-N miproxifene phosphate Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OP(O)(O)=O)=CC=1)\C1=CC=C(OCCN(C)C)C=C1 QZUHFMXJZOUZFI-ZQHSETAFSA-N 0.000 claims description 2
- 229950002366 nafoxidine Drugs 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 19
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 229940022663 acetate Drugs 0.000 claims 3
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000001836 utereotrophic effect Effects 0.000 abstract description 2
- 230000002354 daily effect Effects 0.000 description 9
- 229940127234 oral contraceptive Drugs 0.000 description 8
- 239000003539 oral contraceptive agent Substances 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010047998 Withdrawal bleed Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003217 oral combined contraceptive Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96508397A | 1997-11-06 | 1997-11-06 | |
| PCT/US1998/023427 WO1999024027A2 (en) | 1997-11-06 | 1998-11-04 | Anti-estrogen plus progestin containing oral contraceptives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA68365C2 true UA68365C2 (en) | 2004-08-16 |
Family
ID=25509417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000063196A UA68365C2 (en) | 1997-11-06 | 1998-04-11 | Peroral contraception by combination of anti-estrogen and progestin |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1051179B1 (es) |
| JP (1) | JP2001522798A (es) |
| CN (1) | CN1278732A (es) |
| AR (1) | AR016667A1 (es) |
| AT (1) | ATE304359T1 (es) |
| AU (2) | AU760540B2 (es) |
| BG (1) | BG104451A (es) |
| BR (1) | BR9813982A (es) |
| CA (1) | CA2307210A1 (es) |
| CZ (1) | CZ294155B6 (es) |
| DE (1) | DE69831605T2 (es) |
| DK (1) | DK1051179T3 (es) |
| EA (1) | EA200000492A1 (es) |
| EE (1) | EE04092B1 (es) |
| ES (1) | ES2246541T3 (es) |
| GE (1) | GEP20043290B (es) |
| HR (1) | HRP20000269A2 (es) |
| HU (1) | HUP0100293A3 (es) |
| ID (1) | ID24568A (es) |
| IL (1) | IL135621A0 (es) |
| NO (1) | NO20002167L (es) |
| NZ (1) | NZ503890A (es) |
| PL (1) | PL340623A1 (es) |
| SK (1) | SK6482000A3 (es) |
| TR (1) | TR200001268T2 (es) |
| UA (1) | UA68365C2 (es) |
| WO (1) | WO1999024027A2 (es) |
| ZA (1) | ZA9810136B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
| US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| HRP20000778B1 (en) * | 1998-05-15 | 2004-10-31 | Wyeth Corp | 2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens |
| EP1212335B1 (en) * | 1999-09-13 | 2006-01-18 | Wyeth | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| US6380166B1 (en) | 1999-09-13 | 2002-04-30 | American Home Products Corporation | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols |
| US6376486B1 (en) * | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
| CA2448235A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
| PT1809602E (pt) | 2004-10-27 | 2008-12-15 | Janssen Pharmaceutica Nv | Derivados de indole úteis como moduladores do receptor da progesterona |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| ES2935125T3 (es) | 2015-12-09 | 2023-03-01 | Univ Illinois | Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| BR112018077136A2 (pt) | 2016-07-01 | 2019-04-30 | G1 Therapeutics, Inc. | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| AR110728A1 (es) | 2017-01-06 | 2019-04-24 | G1 Therapeutics Inc | Terapia combinada para el tratamiento del cáncer |
| TW201835064A (zh) | 2017-02-10 | 2018-10-01 | 美商G1治療公司 | 苯并噻吩雌激素受體調節劑 |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CA3067873A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| JP2024523839A (ja) | 2021-06-08 | 2024-07-02 | シーフォー セラピューティクス， インコーポレイテッド | 突然変異体ｂｒａｆを分解する療法薬 |
| KR20250055538A (ko) | 2022-08-03 | 2025-04-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ret 단백질을 조정하기 위한 화합물 |
| JP2025540906A (ja) | 2022-11-04 | 2025-12-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｅｔ－ｌｄｄタンパク質阻害剤 |
| CN120569388A (zh) | 2022-11-04 | 2025-08-29 | 百时美施贵宝公司 | Ret-ldd蛋白降解剂 |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA716118B (en) * | 1970-10-05 | 1972-05-31 | Richardson Merrell Inc | Contraception |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
| ES2162198T3 (es) * | 1996-04-19 | 2001-12-16 | American Home Prod | Agentes estrogenos. |
| US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
-
1998
- 1998-04-11 UA UA2000063196A patent/UA68365C2/uk unknown
- 1998-04-11 ID IDW20000811A patent/ID24568A/id unknown
- 1998-11-04 AU AU13031/99A patent/AU760540B2/en not_active Ceased
- 1998-11-04 PL PL98340623A patent/PL340623A1/xx unknown
- 1998-11-04 EE EEP200000211A patent/EE04092B1/xx not_active IP Right Cessation
- 1998-11-04 CZ CZ20001661A patent/CZ294155B6/cs not_active IP Right Cessation
- 1998-11-04 CN CN98810911A patent/CN1278732A/zh active Pending
- 1998-11-04 AT AT98956525T patent/ATE304359T1/de not_active IP Right Cessation
- 1998-11-04 NZ NZ503890A patent/NZ503890A/xx unknown
- 1998-11-04 HR HR20000269A patent/HRP20000269A2/hr not_active Application Discontinuation
- 1998-11-04 TR TR2000/01268T patent/TR200001268T2/xx unknown
- 1998-11-04 IL IL13562198A patent/IL135621A0/xx unknown
- 1998-11-04 WO PCT/US1998/023427 patent/WO1999024027A2/en not_active Ceased
- 1998-11-04 JP JP2000520119A patent/JP2001522798A/ja not_active Ceased
- 1998-11-04 HU HU0100293A patent/HUP0100293A3/hu unknown
- 1998-11-04 DK DK98956525T patent/DK1051179T3/da active
- 1998-11-04 GE GEAP19985364A patent/GEP20043290B/en unknown
- 1998-11-04 ES ES98956525T patent/ES2246541T3/es not_active Expired - Lifetime
- 1998-11-04 DE DE69831605T patent/DE69831605T2/de not_active Expired - Lifetime
- 1998-11-04 EP EP98956525A patent/EP1051179B1/en not_active Expired - Lifetime
- 1998-11-04 EA EA200000492A patent/EA200000492A1/ru unknown
- 1998-11-04 CA CA002307210A patent/CA2307210A1/en not_active Abandoned
- 1998-11-04 BR BR9813982-7A patent/BR9813982A/pt not_active Application Discontinuation
- 1998-11-04 SK SK648-2000A patent/SK6482000A3/sk unknown
- 1998-11-05 ZA ZA9810136A patent/ZA9810136B/xx unknown
- 1998-11-05 AR ARP980105591A patent/AR016667A1/es not_active Application Discontinuation
-
2000
- 2000-04-27 NO NO20002167A patent/NO20002167L/no not_active Application Discontinuation
- 2000-05-17 BG BG104451A patent/BG104451A/xx unknown
-
2003
- 2003-06-23 AU AU2003204896A patent/AU2003204896B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1051179B1 (en) | Anti-estrogen plus progestin containing oral contraceptives | |
| US6326392B1 (en) | Anti-estrogen plus progestin containing oral contraceptives | |
| US9132137B2 (en) | Graduated estrogen contraceptive | |
| EP0912186B1 (en) | Progestogen-anti-progestogen regimens | |
| US6506390B2 (en) | Progestogen-anti-progestogen regimens | |
| BG62384B1 (bg) | Прогестероново-антагонистични и антиестрогенови активнисъединения с общо приложение за женски контрацептиви | |
| US7935691B2 (en) | Extended cycle multiphasic oral contraceptive kit | |
| CA2566811A1 (en) | Compositions and methods for treatment of premenstrual dysphoric disorder | |
| AU747710B2 (en) | Progestogen-antiprogestogen regimens | |
| RU2002107987A (ru) | Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива | |
| CA2371635A1 (en) | Use of antiprogestagens in combined therapy | |
| MXPA00004610A (es) | Regimenes de progestogeno-anti-progestogeno | |
| HK1019305B (en) | Progestogen-anti-progestogen regimens |